Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
High-risk Human Papillomavirus (HR-HPV)
72%
Head-and-neck Cancer
64%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
54%
Overall Survival
50%
Locally Advanced
46%
Confidence Interval
45%
Head-and-neck
44%
Radiation Therapy
40%
Practical Guide
38%
Induction Chemotherapy
35%
Cisplatin
33%
Disease-specific Survival
31%
Adjuvant Therapy
30%
Hazard Ratio
28%
Neck Dissection
27%
Fibula Free Flap
25%
Disease-free Survival
23%
Nab-paclitaxel
22%
Neoadjuvant
22%
Transoral Laser Microsurgery
22%
Phase II Trial
21%
Transoral Surgery
21%
Fibula
19%
Advanced Stage
18%
Cetuximab
17%
Odds Ratio
17%
Merkel Cell Carcinoma
16%
Locoregional Recurrence
15%
Cisplatin Therapy
15%
Radial Forearm Free Flap
15%
Oncological Outcomes
14%
Free Flap
14%
Multivariable
13%
Nasopharyngeal Carcinoma
13%
National Cancer Database
12%
Swallowing Function
12%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
12%
Pembrolizumab
12%
Surgically Treated
11%
Cancer Outcomes
11%
Clinical Outcomes
11%
Flap
11%
Pharyngocutaneous Fistula
11%
Scapular Flap
11%
Primary Unknown
11%
Laryngectomy
11%
Patterns of Care
11%
Concurrent Cisplatin
11%
Health Outcomes
11%
Medicine and Dentistry
Wart Virus
72%
Head and Neck Cancer
56%
Oropharynx Squamous Cell Carcinoma
50%
Radiation Therapy
50%
Neck
47%
Head and Neck Squamous Cell Carcinoma
47%
Disease
46%
Free Tissue Graft
45%
Overall Survival
44%
Oropharynx Carcinoma
43%
Hazard Ratio
35%
Neoplasm
33%
Malignant Neoplasm
30%
Surgery
29%
Induction Chemotherapy
29%
Adjuvant Therapy
29%
Fibula
28%
Recurrent Disease
26%
Disease Specific Survival
26%
Cisplatin
25%
Disease Free Survival
23%
Transoral Laser Microsurgery
22%
Oral Cavity
20%
Neck Dissection
17%
Biological Marker
17%
Paclitaxel
17%
Odds Ratio
16%
Merkel Cell Carcinoma
16%
Laryngectomy
16%
Squamous Cell Carcinoma
16%
P16
15%
Comorbidity
15%
T Cell
13%
Phase II Trials
13%
Cohort Analysis
13%
Medicine
12%
Scapula
12%
Pembrolizumab
12%
Fistula
12%
Quality of Life
11%
Base
11%
Clinical Trial
11%
Cancer of Unknown Primary Origin
11%
Cetuximab
11%
Nasopharynx Carcinoma
11%
Socioeconomic Status
11%
Lymph Node
10%
Metastatic Carcinoma
10%
Chemoradiotherapy
9%
Cancer
8%